Pyxis Oncology Reports Strong MICVO Clinical Progress, Extends Cash Runway, and Appoints New Interim CEO

summarizeSummary

Pyxis Oncology announced full-year 2025 financial results, highlighted by significant clinical advancements for its lead candidate MICVO, an extended cash runway into Q4 2026, and the appointment of Thomas Civik as Interim CEO.

check_boxKey Events

• Strong Clinical Progress for MICVO

  Completed target enrollment in the Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ R/M HNSCC in Q1 2026. Preliminary data from December 2025 showed a 46% confirmed objective response rate (ORR) for monotherapy and 71% ORR in combination with KEYTRUDA®.

• Extended Cash Runway

  The company reported cash and cash equivalents, including restricted cash, and short-term investments of $68.3 million as of December 31, 2025, which is expected to fund operations into the fourth quarter of 2026.

• FDA Alignment and Fast Track Designation

  Pyxis Oncology obtained feedback and alignment from the FDA regarding the clinical trial design for a planned pivotal monotherapy study in 2L+ R/M HNSCC and MICVO received Fast Track Designation for this indication.

• New Interim Chief Executive Officer

  Thomas Civik, an experienced biotechnology executive, was appointed Interim Chief Executive Officer in February 2026, bringing a proven track record in advancing cancer therapeutics.

auto_awesomeAnalysis

This 8-K filing provides a comprehensive update for Pyxis Oncology, a clinical-stage biotech. While the company reported a net loss of $79.6 million for 2025, the more impactful news for investors includes the successful completion of target enrollment for its Phase 1 MICVO monotherapy study in R/M HNSCC and positive preliminary efficacy data (46% ORR monotherapy, 71% ORR in combination with KEYTRUDA®). The company also secured FDA alignment for a pivotal study design and expects crucial data readouts in mid-2026 and 2H26. Financially, the company's cash and investments of $68.3 million are projected to fund operations into the fourth quarter of 2026, significantly de-risking near-term liquidity concerns. The appointment of Thomas Civik, an experienced biotech executive, as Interim CEO further strengthens leadership. These developments collectively signal strong operational and clinical momentum, providing a clearer path forward for the company's lead asset and enhancing financial stability.